Most Read Articles
Pearl Toh, 18 Feb 2016
Treatment with eluxadoline, a new oral medication, relieved two major symptoms of irritable bowel syndrome with diarrhoea (IBS-D) — abdominal pain and diarrhoea, according to a study based on two phase III randomized controlled trials. [N Engl J Med 2016;374:242-253]
Roshini Claire Anthony, 20 Mar 2018

Individuals with type 2 diabetes (T2D) who initiate therapy with sodium glucose cotransporter-2 (SGLT-2) inhibitors have lower risks of all-cause death and cardiovascular (CV) outcomes, specifically myocardial infarction (MI) and stroke, compared with those who initiate other glucose-lowering therapies, according to results from the CVD-REAL* 2 study.

Jairia Dela Cruz, 05 Mar 2018
Abaloparatide appears to produce significant increases in the bone mass density (BMD), as well as nominal reductions in fractures, in very elderly women with osteoporosis, with a safety profile similar to that in the overall study population, according to a posthoc analysis of the phase III ACTIVE trial.
Jairia Dela Cruz, 09 Jan 2017
The sulfonylurea glimepiride may pose an increased risk of hypoglycaemia in a subgroup of elderly type 2 diabetes (T2D) patients with lower β-cell function when added to a metformin regimen, according to a post-hoc analysis of data from the GENERATION* trial.

Serious, long-term ocular effects seen after bevacizumab treatment vs laser in eyes with ROP

14 Feb 2018

Treatment with bevacizumab for acute-phase retinopathy of prematurity (ROP), compared with laser, is associated with greater incidence of potentially serious and long-term ocular effects as shown by fluorescein angiography (FA), according to a study.

Abnormalities were seen at the periphery (avascular area, vessel leakage, shunts, abnormal vessel branching and tangles) or the posterior pole (hyperfluorescent lesions, absence of foveal avascular zone) in all 20 eyes treated with bevacizumab at 4 years of age.

On the other hand, these lesions were not present in most of the eyes that underwent laser treatment. Among the 19 laser-treated eyes, one had leakage, three had shunts and tangles, and another three had macular abnormalities.

In this single, randomized, controlled trial, the investigators compared structural outcome at age 4 years of eyes treated with intravitreal injection of bevacizumab with that of fellow eyes treated with conventional laser photoablation in type 1 ROP.

All inborn babies with type 1 zone 1 ROP (n=21; 42 eyes) at the Neonatal Intensive Care Unit of the Catholic University in Rome from 1 September 2009 to 31 March 2012 were enrolled. In 21 infants, one eye was randomly assigned to receive an intravitreal injection of 0.5 mg bevacizumab, while the fellow eye underwent conventional laser photoablation.

The investigators performed digital retinal imaging and FA at an average of 4 years following treatment in follow-up. Two experts examined fluorescein angiograms to document retinal and choroidal findings.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Pharmacist - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Pearl Toh, 18 Feb 2016
Treatment with eluxadoline, a new oral medication, relieved two major symptoms of irritable bowel syndrome with diarrhoea (IBS-D) — abdominal pain and diarrhoea, according to a study based on two phase III randomized controlled trials. [N Engl J Med 2016;374:242-253]
Roshini Claire Anthony, 20 Mar 2018

Individuals with type 2 diabetes (T2D) who initiate therapy with sodium glucose cotransporter-2 (SGLT-2) inhibitors have lower risks of all-cause death and cardiovascular (CV) outcomes, specifically myocardial infarction (MI) and stroke, compared with those who initiate other glucose-lowering therapies, according to results from the CVD-REAL* 2 study.

Jairia Dela Cruz, 05 Mar 2018
Abaloparatide appears to produce significant increases in the bone mass density (BMD), as well as nominal reductions in fractures, in very elderly women with osteoporosis, with a safety profile similar to that in the overall study population, according to a posthoc analysis of the phase III ACTIVE trial.
Jairia Dela Cruz, 09 Jan 2017
The sulfonylurea glimepiride may pose an increased risk of hypoglycaemia in a subgroup of elderly type 2 diabetes (T2D) patients with lower β-cell function when added to a metformin regimen, according to a post-hoc analysis of data from the GENERATION* trial.